Yung-Hyo Koh

This inventor holds 17 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 8 EPO patents. Top assignees: Ardea Biosciences, Inc, Ardes Biosciences Inc., Bayer Schering Pharma Ag. Active years: 2007-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yung-Hyo Koh. Retrieved from https://idiyas.com/inventor/yung-hyo-koh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 3)

% Patents Active = 29.4

CIPO Patents = 3

EPO Patents = 8 (Patent Applications = 4)

Average Co-Inventor Count = 4.4

ph-index = 8

Forward Citations = 211(Granted Patents)

Company Filing History:

14 out of 63

Ardea Biosciences, Inc

patents

1 out of 1

Ardes Biosciences Inc.

patent

1 out of 192

Bayer Schering Pharma Ag

patents

4. 1 out of 7

Valeant Research and Development

patents

Years Active: 2007-2015

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8946273 - S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase (2015-02-03),

2. 8716318 - Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors (2014-05-06),

3. 8552043 - [object Object] (2013-10-08),

4. 8481581 - S-triazolyl α-mercaptoacetanilides as inhibitors of HIV reverse transcriptase (2013-07-09),

5. 8354532 - Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV (2013-01-15),

6. 8324223 - Substituted thieno [2,3-d] pyrimidines as HIV inhibitors (2012-12-04),

7. 8227601 - Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV (2012-07-24),

8. 8211898 - Substituted thieno[3,2-d]pyrimidines as HIV inhibitors (2012-07-03),

9. 8106205 - [object Object] (2012-01-31),

10. 8063049 - Inhibitors of MEK (2011-11-22),

11. 8003681 - 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester (2011-08-23),

12. 7947721 - S-triazolyl α-mercaptoacetanilides as inhibitors of HIV reverse transcriptase (2011-05-24),

13. 7897624 - Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors (2011-03-01),

14. 7820664 - Inhibitors of MEK (2010-10-26),

15. 7595324 - Substituted thieno[3,2-D]pyrimidines as HIV inhibitors (2009-09-29),

Title: The Innovator: Yung-Hyo Koh

Introduction:

Yung-Hyo Koh, a prolific inventor based in Irvine, CA, has made significant contributions to the fields of medicine and oncology. With an impressive portfolio of 17 patents, his innovative work has had a profound impact on the treatment of HIV infections and cancer.

Latest Patents:

1. S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase: Yung-Hyo Koh's invention of S-triazolyl α-mercaptoacetanilides has shown promise in inhibiting various strains of HIV reverse transcriptase, offering a potential breakthrough in HIV treatment.

2. Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors: His development of N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N′-alkyl sulfamides as MEK inhibitors presents a novel approach to combatting cancer and hyperproliferative diseases.

Career Highlights:

Yung-Hyo Koh has made significant contributions during his tenure at renowned companies such as Ardea Biosciences, Inc and Valeant Research and Development. His groundbreaking research has paved the way for innovative treatments and therapeutic advancements in the pharmaceutical industry.

Collaborations:

Throughout his career, Yung-Hyo Koh has collaborated closely with esteemed professionals in the field, including notable coworkers Zhi Hong and Jean-Luc Girardet. These collaborations have fostered a dynamic environment for pioneering research and development in the medical field.

Conclusion:

In conclusion, Yung-Hyo Koh's innovative spirit and dedication to scientific advancements have positioned him as a trailblazer in the fields of HIV treatment and oncology. His groundbreaking patents stand as a testament to his commitment to driving progress and innovation in the realm of healthcare.

Profile summary based on public USPTO records.